文献速递肝病消化道肿瘤与早癌

P-I-R分类在预测乙型肝炎合并晚期肝纤维化患者治疗中组织学与临床结局中的效用

The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
PubMed 文献 · Hepatology · 2023-08-23

本研究基于一项随机对照试验的扩展研究,纳入1000例慢性乙型肝炎伴活检证实的显著肝纤维化患者,接受恩替卡韦为基础的治疗超过7年。在727例于治疗第72周进行第二次活检的患者中,对646例肝组织切片充足者比较P-I-R分类与Ishak评分变化。治疗后P-I-R分类可进一步区分Ishak评分稳定患者的组织学结局,且治疗后进展型与肝脏相关事件风险显著升高相关。

要点

  • 治疗前进展型、不确定型、退行型分别占70%、17%、13%,治疗72周后分别占20%、14%、64%。
  • 7年肝细胞癌累积发生率:退行型1.5%、不确定型4.3%、进展型22.8%(p<0.001)。
  • 调整混杂因素后,治疗后进展型肝脏相关事件风险HR为17.77(vs 退行型,95%CI 5.55-56.88)。

核心结论

  • P-I-R分类不仅是评估组织学变化的有意义补充,还可预测临床结局。

研究设计与样本

  • 一项随机对照试验的扩展研究,最初纳入1000例慢性乙型肝炎伴活检证实的显著肝纤维化患者,接受恩替卡韦为基础治疗超过7年。
  • 727例于治疗第72周进行第二次活检,其中646例肝组织切片充足者纳入组织学评估比较。

主要发现

  • 治疗前进展型、不确定型、退行型分别占70%、17%、13%,治疗72周后分别占20%、14%、64%。
  • P-I-R分类可进一步区分Ishak评分稳定患者的组织学结局。
  • 7年肝细胞癌累积发生率:退行型1.5%、不确定型4.3%、进展型22.8%(p<0.001)。
  • 调整年龄、治疗方案、血小板计数、肝硬化、Ishak纤维化评分变化和Laennec分期后,治疗后进展型肝脏相关事件(失代偿、肝细胞癌、死亡/肝移植)HR为17.77(vs 治疗后退行型;95%CI 5.55-56.88)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The predominantly progressive, indeterminate, and predominantly regressive (P-I-R) classification extends beyond staging and provides information on dynamic changes of liver fibrosis. However, the prognostic implication of P-I-R classification is not elucidated. Therefore, in the present research, we investigated the utility of P-I-R classification in predicting the on-treatment clinical outcomes. APPROACH AND RESULTS: In an extension study on a randomized controlled trial, we originally enrolled 1000 patients with chronic hepatitis B and biopsy-proven histological significant fibrosis, and treated them for more than 7 years with entecavir-based therapy. Among the 727 patients with a second biopsy at treatment week 72, we compared P-I-R classification and Ishak score changes in 646 patients with adequate liver sections for the histological evaluation. Progressive, indeterminate, and regressive cases were observed in 70%, 17%, and 13% of patients before treatments and 20%, 14%, and 64% after 72-week treatment, respectively, which could further differentiate the histological outcomes of patients with stable Ishak scores. The 7-year cumulative incidence of HCC was 1.5% for the regressive cases, 4.3% for the indeterminate cases, and 22.8% for the progressive cases ( p <0.001). After adjusting for age, treatment regimen, platelet counts, cirrhosis, Ishak fibrosis score changes, and Laennec staging, the posttreatment progressive had a HR of 17.77 (vs. posttreatment regressive; 95% CI: 5.55-56.88) for the incidence of liver-related events (decompensation, HCC, and death/liver transplantation). CONCLUSIONS: The P-I-R classification can be a meaningful complement to the Ishak fibrosis score not only in evaluating the histological changes but also in predicting the clinical outcomes.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Chang X, Lv C, Wang B, et al. The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis. Hepatology. 2023. PMID: 37611260. doi:10.1097/HEP.0000000000000563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。